Urmărește-ne
RO
RO

Unul din obiectivele principale ale Life4me+ - să prevină apariția unor noi cazuri de infecție cu HIV, boli cu transmitere sexuală (TBS), hepatită C și tuberculoză

Aplicația permite stabilirea unei comunicări anonime între medici și persoane care au HIV. Îți permite să organizezi mai ușor programul de administrare a tratamentului și să setezi notificări personalizate și discrete

Toate știrile / Aprilie 2017

Arhivă

✕
25 aprilie 2017
5456
Life4me+ EE App Starts in Estonia – A Meeting With Healthcare Leaders In Tallinn

Life4me+ EE App Starts in Estonia – A Meeting With Healthcare Leaders In Tallinn

A meeting between the Life4me+ EE team and the leaders of the Estonian National Institute for Health Development was held in Tallinn yesterday. The Life4me+ EE sales director in the Baltic region Alexander Tamm received ideas and comments from Institute's representatives ...
24 aprilie 2017
5217
97% Cures of Genotype 3 Hep C In Glecaprevir and Pibrentasvir Combination

97% Cures of Genotype 3 Hep C In Glecaprevir and Pibrentasvir Combination

#AbbVie’s pangenotypic direct-acting antiviral combination of two drugs — glecaprevir and pibrentasvir — cured 97% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the ...
24 aprilie 2017
7643
One vs. Many: The Accuracy Of HIV Rapid Diagnostic Tests

One vs. Many: The Accuracy Of HIV Rapid Diagnostic Tests

Médecins Sans Frontières (MSF) has carried out an assessment of the HIV tests accuracy in five sub-Saharan African countries confirming the necessity to accurately choose multiple HIV rapid diagnostic tests in an algorithm/sequence for performing an HIV diagnosis.
24 aprilie 2017
5238
Estonian version of Life4me+ EE App for HIV-positive persons

Estonian version of Life4me+ EE App for HIV-positive persons

Life4me+ team releases the Estonian version of its App for HIV-positive persons translated to the Estonian language
21 aprilie 2017
5021
Defective HIV Proviruses Prevent Immune Possible Cure, John Hopkins Scientists Suggest

Defective HIV Proviruses Prevent Immune Possible Cure, John Hopkins Scientists Suggest

Proteins created by broken forms of HIV previously believed to be harmless interact with the immune system and are actively controlled by a particular type of immune cell, called cytotoxic T-cells, researchers at Johns Hopkins and George Washington universities report a ...
21 aprilie 2017
11727
First HIV PEP/PrEP Centre In Europe Is To Open In Barcelona

First HIV PEP/PrEP Centre In Europe Is To Open In Barcelona

The First in Europe PEP/PrEP Center will be opened in September 2017. Barcelona Checkpoint has initiated the construction of the Center to be named ’Barcelona PrEPPoint,’ the primary purpose of which will be the popularization of pre- and post-exposure prophylaxis for HIV — ...
21 aprilie 2017
5000
Burkitt’s HIV-associated Lymphoma — Mechanism Of The Development Revealed

Burkitt’s HIV-associated Lymphoma — Mechanism Of The Development Revealed

The risk of developing Burkitt's lymphoma is extremely high at the terminal stages of HIV according to the results of a Russian study conducted by a group of scientists from the MSU's A.N. Belozersky Research Institute of Physico-Chemical Biology.
20 aprilie 2017
5431
Restaurant Fundraising Helps People With HIV/AIDS

Restaurant Fundraising Helps People With HIV/AIDS

Thursday is “Dining Out For Life.” If you live in the U. S. or Canada you can help fund services for people with HIV and AIDS simply by going out to dinner.
19 aprilie 2017
5568
New Study Of Cabotegravir As Injectable HIV Medication Started

New Study Of Cabotegravir As Injectable HIV Medication Started

A study to evaluate whether a new injectable medication cabotegravir can work as well as an existing oral pill to protect safely against HIV among men who have sex with men and transgender women who have sex with men launched by The HIV Prevention Trials Network.
19 aprilie 2017
5426
PrEP For Injection Drug Users: Bangkok Tenofovir Study

PrEP For Injection Drug Users: Bangkok Tenofovir Study

People who inject drugs are likely to choose PrEP, according to the Bangkok Tenofovir Study report in The Lancet HIV April issue.
Folosim cookies pentru a-ți îmbunătăți experiența pe acest site.
Apasând click pe oricare dintre butoane de pe acest site, îți exprimi acordul ca noi să folosim setările din cookies.